🧾 What This Document Is

This is a DEFA14A filing, which stands for "Definitive Additional Materials" related to a proxy statement. Think of it as an update or supplement to an earlier proxy announcement. In this case, Amneal is using it to formally file and explain materials it shared on social media about a major deal and its latest earnings.

👉 Why it matters: It’s the official SEC record of the company’s announcement to shareholders about a significant acquisition and strong quarterly performance.

🏢 What The Company Does

Amneal Pharmaceuticals (AMRX) is a global pharmaceutical company. In simple terms, it develops, manufactures, and sells generic medicines and biosimilars (near-copies of biologic drugs).

👉 The company is now taking a strategic step to expand its biosimilar capabilities with this acquisition.

🤝 The Deal: Acquiring Kashiv BioSciences

The big news is Amneal’s agreement to buy 100% of Kashiv BioSciences, LLC, a fully integrated biopharmaceutical company.

• What Kashiv is: A company that handles everything from development to manufacturing of biologic drugs.
• Deal Date: The purchase agreement was signed on April 21, 2026.
• Key Conditions: The deal is not final. It requires approval from Amneal's shareholders, regulatory green lights, and other standard closing conditions.
• Why it’s a big move: This acquisition is a clear signal that Amneal is aggressively investing to build its presence in the high-growth biosimilars market, moving beyond traditional generics.

📊 Strong Start to the Year: Preliminary Q1 Results

Alongside the deal news, Amneal reported very strong preliminary results for the first quarter of 2026, showing great momentum.

• Net Revenue: $723 million, a 4% increase.
• Income Before Tax: $80 million, a massive 114% jump.
• Adjusted EBITDA: $202 million, up 19%. 👉 The company is firing on all cylinders financially as it pursues this major acquisition.

💡 Understanding "Adjusted EBITDA"

The filing spends time explaining this non-GAAP financial measure (Adjusted EBITDA of $202M).

• What it is: It's a customized profit metric that strips out certain costs (like interest, taxes, and some non-cash items) to show what management believes is the core operational performance.
• The Catch: It’s not an official accounting number (GAAP), and other companies might calculate it differently. It should be viewed alongside standard financial statements, not instead of them.
• Why companies use it: Amneal says it helps internal and external investors evaluate the underlying business trends, free from some accounting complexities.

👥 Who's Involved & Next Steps

Because this is a proxy-related filing, it outlines the "solicitation" process for the shareholder vote.

• Participants: Amneal itself, its directors, and certain executives are involved in soliciting votes for the deal's approval.
• Their Stakes: Details about their stock ownership were previously filed and can be found in the company’s 2026 annual meeting proxy.
• Investor Contact: The company directs questions to its Investor Relations team:

  Investor Relations, 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807 Email: [email protected]

🧠 The Analogy

This filing is like a homeowner (Amneal) who just had a stellar quarter at work (great Q1 results) and immediately announces plans to buy and renovate a neighboring property (Kashiv) to significantly upgrade their living space (biosimilar business). They’re now sending the formal paperwork to their family partners (shareholders) for approval, showing them both their strong paycheck and the blueprints for the renovation.

🧩 Final Takeaway

Amneal is using its strong financial momentum to make a major strategic push into biologics by acquiring Kashiv BioSciences. The deal is announced but pending shareholder approval. The company’s excellent Q1 performance provides a solid foundation for this ambitious move.